Literature DB >> 23041230

Rat CYP24A1 acts on 20-hydroxyvitamin D(3) producing hydroxylated products with increased biological activity.

Elaine W Tieu1, Edith K Y Tang, Jianjun Chen, Wei Li, Minh N Nguyen, Zorica Janjetovic, Andrzej Slominski, Robert C Tuckey.   

Abstract

20-Hydroxyvitamin D(3) (20(OH)D(3)), the major product of CYP11A1 action on vitamin D(3), is biologically active and is produced in vivo. As well as potentially having important physiological actions, it is of interest as a therapeutic agent due to its lack of calcemic activity. In the current study we have examined the ability of CYP24A1, the enzyme that inactivates 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)), to metabolize 20(OH)D(3). Rat CYP24A1 was expressed in Escherichia coli, purified by Ni-affinity chromatography and assayed with substrates incorporated into phospholipid vesicles which served as a model of the inner mitochondrial membrane. In this system CYP24A1 metabolized 1,25(OH)(2)D(3) with a catalytic efficiency 1.4-fold higher than that seen for 25-hydroxyvitamin D(3) (25(OH)D(3)). CYP24A1 hydroxylated 20(OH)D(3) to several dihydroxy-derivatives with the major two identified by NMR as 20,24-dihydroxyvitamin D(3) (20,24(OH)(2)D(3)) and 20,25-dihydroxyvitamin D(3) (20,25(OH)(2)D(3)). The catalytic efficiency of CYP24A1 for 20(OH)D(3) metabolism was more than 10-fold lower than for either 25(OH)D(3) or 1,25(OH)(2)D(3) and no secondary metabolites were produced. The two major products, 20,24(OH)(2)D(3) and 20,25(OH)(2)D(3), caused significantly greater inhibition of colony formation by SKMEL-188 melanoma cells than either 1,25(OH)(2)D(3) or the parent 20(OH)D(3), showing that CYP24A1 plays an activating, rather than an inactivating role on 20(OH)D(3).
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23041230      PMCID: PMC3501553          DOI: 10.1016/j.bcp.2012.09.032

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  52 in total

1.  1,25(OH)2D, the preferred substrate for CYP24.

Authors:  Glenville Jones; Harriet S Tenenhouse
Journal:  J Bone Miner Res       Date:  2002-01       Impact factor: 6.741

Review 2.  New vitamin D analogs as potential therapeutics in melanoma.

Authors:  Paulina Szyszka; Michal A Zmijewski; Andrzej T Slominski
Journal:  Expert Rev Anticancer Ther       Date:  2012-05       Impact factor: 4.512

3.  The potential role of vitamin D in the progression of benign and malignant melanocytic neoplasms.

Authors:  Joel Pinczewski; Andrzej Slominski
Journal:  Exp Dermatol       Date:  2010-10       Impact factor: 3.960

4.  Chemical synthesis of 20S-hydroxyvitamin D3, which shows antiproliferative activity.

Authors:  Wei Li; Jianjun Chen; Zorica Janjetovic; Tae-Kang Kim; Trevor Sweatman; Yan Lu; Jordan Zjawiony; Robert C Tuckey; Duane Miller; Andrzej Slominski
Journal:  Steroids       Date:  2010-06-11       Impact factor: 2.668

5.  Cytochrome P-450scc-substrate interactions. Studies of binding and catalytic activity using hydroxycholesterols.

Authors:  J D Lambeth; S E Kitchen; A A Farooqui; R Tuckey; H Kamin
Journal:  J Biol Chem       Date:  1982-02-25       Impact factor: 5.157

6.  The concentration of adrenodoxin reductase limits cytochrome p450scc activity in the human placenta.

Authors:  R C Tuckey; J Sadleir
Journal:  Eur J Biochem       Date:  1999-07

7.  Correlation between secosteroid-induced vitamin D receptor activity in melanoma cells and computer-modeled receptor binding strength.

Authors:  Tae-Kang Kim; Jin Wang; Zorica Janjetovic; Jianjun Chen; Robert C Tuckey; Minh N Nguyen; Edith K Y Tang; Duane Miller; Wei Li; Andrzej T Slominski
Journal:  Mol Cell Endocrinol       Date:  2012-04-21       Impact factor: 4.102

8.  Products of vitamin D3 or 7-dehydrocholesterol metabolism by cytochrome P450scc show anti-leukemia effects, having low or absent calcemic activity.

Authors:  Andrzej T Slominski; Zorica Janjetovic; Brian E Fuller; Michal A Zmijewski; Robert C Tuckey; Minh N Nguyen; Trevor Sweatman; Wei Li; Jordan Zjawiony; Duane Miller; Tai C Chen; Gerard Lozanski; Michael F Holick
Journal:  PLoS One       Date:  2010-03-26       Impact factor: 3.240

9.  Pathways and products for the metabolism of vitamin D3 by cytochrome P450scc.

Authors:  Robert C Tuckey; Wei Li; Jordan K Zjawiony; Michal A Zmijewski; Minh N Nguyen; Trevor Sweatman; Duane Miller; Andrzej Slominski
Journal:  FEBS J       Date:  2008-04-10       Impact factor: 5.542

10.  Isolation and expression of human 1,25-dihydroxyvitamin D3 24-hydroxylase cDNA.

Authors:  K S Chen; J M Prahl; H F DeLuca
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

View more
  31 in total

1.  Metabolism of 20-hydroxyvitamin D3 and 20,23-dihydroxyvitamin D3 by rat and human CYP24A1.

Authors:  Elaine W Tieu; Wei Li; Jianjun Chen; Tae-Kang Kim; Dejian Ma; Andrzej T Slominski; Robert C Tuckey
Journal:  J Steroid Biochem Mol Biol       Date:  2015-02-26       Impact factor: 4.292

2.  Properties of purified CYP2R1 in a reconstituted membrane environment and its 25-hydroxylation of 20-hydroxyvitamin D3.

Authors:  Chloe Y S Cheng; Tae-Kang Kim; Saowanee Jeayeng; Andrzej T Slominski; Robert C Tuckey
Journal:  J Steroid Biochem Mol Biol       Date:  2017-07-14       Impact factor: 4.292

Review 3.  The role of CYP11A1 in the production of vitamin D metabolites and their role in the regulation of epidermal functions.

Authors:  Andrzej T Slominski; Tae-Kang Kim; Wei Li; Ae-Kyung Yi; Arnold Postlethwaite; Robert C Tuckey
Journal:  J Steroid Biochem Mol Biol       Date:  2013-10-28       Impact factor: 4.292

Review 4.  Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management.

Authors:  Andrzej T Slominski; Anna A Brożyna; Michal A Zmijewski; Wojciech Jóźwicki; Anton M Jetten; Rebecca S Mason; Robert C Tuckey; Craig A Elmets
Journal:  Lab Invest       Date:  2017-02-20       Impact factor: 5.662

5.  Novel vitamin D analogs as potential therapeutics: metabolism, toxicity profiling, and antiproliferative activity.

Authors:  Jianjun Chen; Jin Wang; Tae-Kang Kim; Elaine W Tieu; Edith K Y Tang; Zongtao Lin; Dianne Kovacic; Duane D Miller; Arnold Postlethwaite; Robert C Tuckey; Andrzej T Slominski; Wei Li
Journal:  Anticancer Res       Date:  2014-05       Impact factor: 2.480

6.  Bioactive forms of vitamin D selectively stimulate the skin analog of the hypothalamus-pituitary-adrenal axis in human epidermal keratinocytes.

Authors:  Justyna M Wierzbicka; Michał A Żmijewski; Anna Piotrowska; Boguslaw Nedoszytko; Magdalena Lange; Robert C Tuckey; Andrzej T Slominski
Journal:  Mol Cell Endocrinol       Date:  2016-08-12       Impact factor: 4.102

7.  Hydroxylation of CYP11A1-derived products of vitamin D3 metabolism by human and mouse CYP27B1.

Authors:  Edith K Y Tang; Jianjun Chen; Zorica Janjetovic; Elaine W Tieu; Andrzej T Slominski; Wei Li; Robert C Tuckey
Journal:  Drug Metab Dispos       Date:  2013-03-01       Impact factor: 3.922

8.  Design, Synthesis and Biological Activities of Novel Gemini 20S-Hydroxyvitamin D3 Analogs.

Authors:  Zongtao Lin; Srinivasa R Marepally; Tae-Kang Kim; Zorica Janjetovic; Allen Sw Oak; Arnold E Postlethwaite; Linda K Myers; Robert C Tuckey; Andrzej T Slominski; Duane D Miller; Wei Li
Journal:  Anticancer Res       Date:  2016-03       Impact factor: 2.480

9.  Hydroxylation of 20-hydroxyvitamin D3 by human CYP3A4.

Authors:  Chloe Y S Cheng; Andrzej T Slominski; Robert C Tuckey
Journal:  J Steroid Biochem Mol Biol       Date:  2016-03-09       Impact factor: 4.292

Review 10.  The Role of Classical and Novel Forms of Vitamin D in the Pathogenesis and Progression of Nonmelanoma Skin Cancers.

Authors:  Andrzej T Slominski; Anna A Brożyna; Michal A Zmijewski; Zorica Janjetovic; Tae-Kang Kim; Radomir M Slominski; Robert C Tuckey; Rebecca S Mason; Anton M Jetten; Purushotham Guroji; Jörg Reichrath; Craig Elmets; Mohammad Athar
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.